Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline

Share this article:

A two-year study of HIV drug regimens shows Gilead's Striblid quad pill edges out three-part Atripla in virus suppression, with 84% of quad pill patients reaching undetectable levels compared with viral suppression of 82% of patients on Atripla, which is co-marketed by Gilead and Bristol-Myers Squibb, reports Medpage Today. The findings showed similar efficacy among patients younger than 40 and older than 40, and across sexes and ethnic backgrounds.

GlaxoSmithKline submitted an sNDA to the FDA so its BRAF inhibitor dabrafenib and MEK inhibitor trametinib can be paired up to treat metastatic melanoma. GSK submitted sNDAs for each of the drugs so they can be used in a two-for-one setting. Phase II studies comparing dabrafenib monotherapy vs. combination treatment are the basis of the proposal. The drug maker's oncology efforts also include its recent deal with the British biotech Immunocore. The deal focuses on developing ImmTACs to treat cancers and viral diseases. The deal gives $181 million to Immunocore now, with the promise of up to $255 million in additional milestone payments.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.